Related Experiment Video
Updated: Aug 16, 2025
Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
Published on: May 10, 2024
Advancing gastric cancer precision medicine with novel genomic screens†
Nicole B Halmai1,2, Luis G Carvajal-Carmona1,2,3
1Genome Center, University of California at Davis, Davis, CA, USA.
Abstract:
A recent study published in The Journal of Pathology used an shRNA library targeting all known human genes involved in metabolism to identify genes important for gastric cancer. The screen identified aspartyl-tRNA synthetase (DARS) as a potential drug target, and patients whose tumors had high DARS levels had a worse prognosis, particularly among diffuse-type gastric cancer. These findings identify a potential therapeutic target for precision medicine of gastric cancer patients, and may be useful for further investigations to discover additional interacting targets. © 2022 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
Insights
Researchers identified aspartyl-tRNA synthetase (DARS) as a key gene in gastric cancer metabolism. High DARS levels correlate with a worse prognosis, especially in diffuse-type gastric cancer, suggesting DARS as a potential therapeutic target.
Area of Science:
- Oncology
- Molecular Biology
- Metabolic Research
Background:
- Gastric cancer is a leading cause of cancer-related mortality worldwide.
- Identifying novel therapeutic targets is crucial for improving patient outcomes.
- Metabolic alterations are increasingly recognized as hallmarks of cancer.
Purpose of the Study:
- To identify novel genes critical for gastric cancer progression using a large-scale genetic screen.
- To evaluate aspartyl-tRNA synthetase (DARS) as a potential therapeutic target in gastric cancer.
- To correlate DARS expression levels with patient prognosis.
Main Methods:
- Utilized a human gene-targeting shRNA library focused on metabolic genes.
- Conducted a high-throughput screen to identify genes essential for gastric cancer cell survival.
- Analyzed DARS expression in patient tumor samples and correlated with clinical data.
Main Results:
- Aspartyl-tRNA synthetase (DARS) was identified as a key gene in gastric cancer.
- High DARS expression in tumors was associated with a poorer prognosis.
- This association was particularly significant in diffuse-type gastric cancer patients.
Conclusions:
- DARS represents a potential therapeutic target for precision medicine in gastric cancer.
- Targeting DARS may offer a novel treatment strategy for specific patient subgroups.
- Further research into DARS-interacting targets could uncover additional therapeutic avenues.
More Related Videos
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
10:28Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
Related Concept Videos
02:46Genetic Screens
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...